Invesco Ltd. Purchases 3,394,330 Shares of Gilead Sciences, Inc. $GILD

Invesco Ltd. raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 33.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 13,521,228 shares of the biopharmaceutical company’s stock after buying an additional 3,394,330 shares during the quarter. Invesco Ltd.’s holdings in Gilead Sciences were worth $1,499,098,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Rothschild Investment LLC raised its holdings in Gilead Sciences by 1.9% during the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after buying an additional 84 shares during the last quarter. Archer Investment Corp raised its stake in shares of Gilead Sciences by 1.2% during the 2nd quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock worth $807,000 after purchasing an additional 87 shares during the period. EPG Wealth Management LLC boosted its stake in Gilead Sciences by 2.0% in the second quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company’s stock valued at $513,000 after acquiring an additional 89 shares during the last quarter. Southland Equity Partners LLC grew its position in shares of Gilead Sciences by 2.9% during the 2nd quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock valued at $364,000 after acquiring an additional 92 shares during the period. Finally, Putney Financial Group LLC increased its stake in shares of Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the completion of the sale, the insider directly owned 107,193 shares in the company, valued at $13,491,310.98. The trade was a 20.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the transaction, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This represents a 1.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 135,757 shares of company stock valued at $16,616,127 in the last 90 days. 0.27% of the stock is owned by company insiders.

Gilead Sciences Trading Down 0.3%

Shares of GILD stock opened at $123.91 on Wednesday. The company has a market capitalization of $153.73 billion, a PE ratio of 19.21, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32. Gilead Sciences, Inc. has a 52-week low of $88.57 and a 52-week high of $128.70. The business’s fifty day moving average is $120.30 and its 200 day moving average is $115.02. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the previous year, the business earned $2.02 earnings per share. The firm’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio is 48.99%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on GILD shares. UBS Group raised their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. Wells Fargo & Company upped their price objective on shares of Gilead Sciences from $140.00 to $145.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Wall Street Zen raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. Finally, Argus boosted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $130.65.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.